期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Clinical Effect of Ilaprazole Enteric-Coated Tablets in Patients with Peptic Ulcer
1
作者 Fanghui Chen 《Journal of Biosciences and Medicines》 2024年第9期155-160,共6页
Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were sele... Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance. 展开更多
关键词 Ilaprazole enteric-coated tablets Peptic Ulcer SYMPTOMS
下载PDF
Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction
2
作者 Yiru Chen 《Journal of Clinical and Nursing Research》 2024年第6期290-294,共5页
Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from Janu... Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized. 展开更多
关键词 Clopidogrel bisulfate Aspirin enteric-coated tablets Acute myocardial infarction
下载PDF
Gradient high performance liquid chromatography method for simultaneous determination of ilaprazole and its related impurities in commercial tablets 被引量:2
3
作者 Shang Wang Dong Zhang +3 位作者 Yingli Wang Xiaohong Liu Yan Liu Lu Xu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2015年第2期146-151,共6页
A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was car... A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets. 展开更多
关键词 Ilaprazole enteric-coated tablets Related impurities HPLC Validation
下载PDF
Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor:A case report
4
作者 Fabio Frosio Emanuele Rausa +2 位作者 Paolo Marra Marie-Christine Boutron-Ruault Alessandro Lucianetti 《World Journal of Clinical Cases》 SCIE 2022年第19期6710-6715,共6页
BACKGROUND Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon.Before dissolution of the enteric coating,they ma... BACKGROUND Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon.Before dissolution of the enteric coating,they may appear hyperdense on computed tomography(CT).Unfortunately,few reports have been published on this topic so far.In this case report,the hyperdense appearance on contrastenhanced CT of an enteric-coated mesalamine tablet was initially misinterpreted as a jejunal gastrointestinal stromal tumor(GIST).CASE SUMMARY An asymptomatic 81-year-old male patient,who had undergone laparoscopic right nephrectomy four years earlier for stage 1 renal carcinoma,was diagnosed with a jejunal GIST at the 4-year follow-up thoraco-abdominal CT scan.He was referred to our hub hospital for gastroenterological evaluation,and subsequently underwent 18-fluorodeoxyglucose positron emission tomography,abdominal magnetic resonance imaging,and video capsule endoscopy.None of these examinations detected any lesion of the small intestine.After reviewing all the CT images in a multidisciplinary setting,the panel estimated that the hyperdense jejunal image was consistent with a tablet rather than a GIST.The tablet was an 800 mg delayed-release enteric-coated oral mesalamine tablet(Asacol®),which had been prescribed for non-specific colitis,while not informing the hospital physicians.CONCLUSION Delayed-release oral mesalamine(Asacol®),like other enteric-coated medications,can appear as a hyperdense image on a CT scan,mimicking a small intestinal GIST.Therefore,adetailed knowledge of the patients’medications and a multidisciplinary review of the images areessential. 展开更多
关键词 MESALAMINE enteric-coating Asacol tablet Gastrointestinal stromal tumor Case report
下载PDF
舍雷肽酶肠溶片对慢性鼻窦炎疾病肿胀的疗效及安全性评估 被引量:1
5
作者 郑晶琼 虞义建 潘兆虎 《中国现代医生》 2017年第12期84-87,共4页
目的探讨舍雷肽酶肠溶片治疗慢性鼻窦炎疾病肿胀的临床疗效及安全性。方法纳入172例慢性鼻窦炎患者,均具有完整的临床资料,收集时间为2014年10月~2016年10月。按照就诊顺序进行分组,分为对照组(85例)和观察组(87例),分别给予克拉霉素治... 目的探讨舍雷肽酶肠溶片治疗慢性鼻窦炎疾病肿胀的临床疗效及安全性。方法纳入172例慢性鼻窦炎患者,均具有完整的临床资料,收集时间为2014年10月~2016年10月。按照就诊顺序进行分组,分为对照组(85例)和观察组(87例),分别给予克拉霉素治疗和克拉霉素联合舍雷肽酶肠溶片治疗。观察两组治疗前后的临床症状和体征评分及生活质量评分,判定疗效并记录不良反应情况。结果治疗后两组患者的临床症状和体征评分与本组治疗前进行比较,均出现显著下降,差异有统计学意义(P<0.05),且治疗后观察组评分显著低于对照组,组间比较差异有统计学意义(P<0.05);观察组显效50例,有效31例,总有效率为93.10%,显著高于对照组的82.35%(P<0.05);治疗前与治疗后不同时间分别对两组患者进行鼻腔鼻窦结局测量20条(SNOT-20)评分比较,与本组治疗前比较,治疗后1个月、2个月、3个月评分均出现显著的下降(P<0.05),且治疗后不同时间点观察组评分显著低于对照组,组间比较差异有统计学意义(P<0.05);研究过程中两组患者均未出现不良反应。结论对慢性鼻窦炎患者实施舍雷肽酶肠溶片治疗可以有效改善患者的临床肿胀等症状,提高治疗效果以及患者的生活质量,且无不良反应,是一种安全有效的治疗方案。 展开更多
关键词 慢性鼻窦炎 舍雷肽酶肠溶片 肿胀 安全性
下载PDF
舍雷肽酶肠溶片联合鼻内糖皮质激素对慢性鼻-鼻窦炎术后黏膜恢复的疗效观察 被引量:2
6
作者 欧劲 朱献文 《中国当代医药》 CAS 2021年第18期26-29,共4页
目的探讨舍雷肽酶肠溶片联合鼻内糖皮质激素对慢性鼻-鼻窦炎术后黏膜恢复的临床疗效。方法选取2017年1月~2019年10月罗定市人民医院收治的44例慢性鼻-鼻窦炎患者作为研究对象,按照随机数字表法分为观察组(22例)与对照组(22例)。两组患... 目的探讨舍雷肽酶肠溶片联合鼻内糖皮质激素对慢性鼻-鼻窦炎术后黏膜恢复的临床疗效。方法选取2017年1月~2019年10月罗定市人民医院收治的44例慢性鼻-鼻窦炎患者作为研究对象,按照随机数字表法分为观察组(22例)与对照组(22例)。两组患者均完成功能性鼻内镜手术,对照组给予糠酸莫米松鼻喷雾剂术后喷鼻,观察组则在对照组基础上口服舍雷肽酶肠溶片。比较两组治疗前后临床症状评分及Lund-Kennedy评分变化。结果两组治疗前临床症状评分比较,差异无统计学意义(P>0.05);治疗后两组的鼻塞、流脓涕、头痛及嗅觉下降评分均低于治疗前,且观察组各项评分低于对照组,差异有统计学意义(P<0.05)。两组治疗前Lund-Kennedy评分比较,差异无统计学意义(P>0.05);治疗后两组的Lund-Kennedy评分均低于治疗前,且观察组Lund-Kennedy评分低于对照组,差异有统计学意义(P<0.05)。结论慢性鼻窦炎患者术后,采用舍雷肽酶肠溶片口服联合鼻内糖皮质激素喷鼻,可加强黏膜消肿作用,促进鼻腔鼻窦黏膜恢复,具有较好的临床应用价值。 展开更多
关键词 慢性鼻-鼻窦炎 舍雷肽酶肠溶片 鼻内糖皮质激素 鼻黏膜 Lund-Kennedy评分
下载PDF
舍雷肽酶肠溶片联合噻托溴铵治疗支气管扩张症的疗效观察 被引量:11
7
作者 杨丹芬 谢加利 《现代药物与临床》 CAS 2016年第12期1946-1949,共4页
目的探讨舍雷肽酶肠溶片联合噻托溴铵粉吸入剂治疗支气管扩张症的临床疗效。方法对2015年9月—2016年9月在延安大学附属医院接受治疗的86例支气管扩张症患者临床资料进行回顾性分析,根据治疗方案的差别分为治疗组和对照组,每组各43例。... 目的探讨舍雷肽酶肠溶片联合噻托溴铵粉吸入剂治疗支气管扩张症的临床疗效。方法对2015年9月—2016年9月在延安大学附属医院接受治疗的86例支气管扩张症患者临床资料进行回顾性分析,根据治疗方案的差别分为治疗组和对照组,每组各43例。对照组用吸入器吸入噻托溴铵粉吸入剂,18μg/次,1次/d。治疗组在对照组基础上口服舍雷肽酶肠溶片,1片/次,3次/d。两组患者均连续治疗7 d。观察两组的临床疗效,比较两组治疗前后咳嗽程度评分、咳痰量评分、肺部啰音评分、第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流速(PEF)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为81.40%、97.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者咳嗽程度评分、咳痰量评分、肺部啰音评分均显著降低,FEV1、FVC、PEF均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后治疗组咳嗽程度评分、咳痰量评分、肺部啰音评分低于对照组,FEV1、FVC、PEF高于对照组,两组比较差异具有统计学意义(P<0.05)。结论舍雷肽酶肠溶片联合噻托溴铵粉吸入剂治疗支气管扩张症具有较好的临床疗效,可明显改善患者的临床症状和肺功能,具有一定的临床推广应用价值。 展开更多
关键词 舍雷肽酶肠溶片 噻托溴铵粉吸入剂 支气管扩张症 咳嗽程度评分 第一秒用力呼气容积
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部